Related Experiment Videos
Reprogramming Adenosine-Driven Tumor Immunosuppression With a Carrier-Free Nanoplatform for Self-Amplifying Antitumor
Yang Ming1, Zhichu Xiang2, Mengyao Zhao3
1Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Small (Weinheim an Der Bergstrasse, Germany)
|August 10, 2026
Summary
This study introduces a novel nanoplatform that reprograms the tumor microenvironment by boosting extracellular ATP (eATP) and blocking its conversion to adenosine. This strategy enhances antitumor immunity and therapeutic efficacy.
Area of Science:
- Biomedical Engineering
- Cancer Immunology
- Drug Delivery
Background:
- The tumor microenvironment (TME) is characterized by dysregulated purinergic signaling, impacting antitumor immunity.
- Immunogenic cell death (ICD) releases extracellular ATP (eATP), but ectonucleotidases rapidly degrade it to immunosuppressive adenosine, limiting therapy effectiveness.
Purpose of the Study:
- To develop a biomimetic nanoplatform that reprograms the TME by promoting eATP accumulation and inhibiting adenosine production.
- To overcome adenosine-mediated immunosuppression for enhanced cancer immunotherapy.
Main Methods:
- Engineered a carrier-free nanoplatform (CADF@TA) via coordination-driven self-assembly.
- Co-assembled ectonucleotidase inhibitor ARL-67156 (ARL), CpG oligonucleotide, Fe2+, and doxorubicin (DOX).
- Utilized a "pump-and-lock" mechanism where DOX induces ICD and ATP release, while ARL inhibits CD39/CD73 to prevent ATP degradation.
Main Results:
- The nanoplatform establishes a sustained eATP-enriched TME, promoting immune cell recruitment.
- CpG adjuvant facilitates dendritic cell maturation and T cell activation (CD4+ and CD8+).
- The system creates a self-amplifying immunostimulatory feedback loop, enhancing tumor apoptosis.
Conclusions:
- The carrier-free nanoplatform effectively overcomes adenosine-mediated immunosuppression through metabolic reprogramming.
- This approach enables a self-amplifying immunostimulatory cascade for improved antitumor therapy.
- The study presents a promising strategy for enhancing cancer treatment by modulating the tumor microenvironment's bioenergetics and immune response.